Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Cipla
Covington
Dow
Harvard Business School
Julphar
Colorcon
Novartis
McKinsey
Mallinckrodt

Generated: January 18, 2018

DrugPatentWatch Database Preview

NEOSAR Drug Profile

« Back to Dashboard

When do Neosar patents expire, and when can generic versions of Neosar launch?

Neosar is a drug marketed by Bedford and Teva Parenteral and is included in two NDAs.

The generic ingredient in NEOSAR is cyclophosphamide. There are eighteen drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the cyclophosphamide profile page.

US Patents and Regulatory Information for NEOSAR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bedford NEOSAR cyclophosphamide INJECTABLE;INJECTION 087442-004 Jul 8, 1983 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Teva Parenteral NEOSAR cyclophosphamide INJECTABLE;INJECTION 040015-005 Apr 29, 1993 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Bedford NEOSAR cyclophosphamide INJECTABLE;INJECTION 087442-002 Feb 16, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Teva Parenteral NEOSAR cyclophosphamide INJECTABLE;INJECTION 040015-001 Apr 29, 1993 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Bedford NEOSAR cyclophosphamide INJECTABLE;INJECTION 087442-005 Mar 30, 1989 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Bedford NEOSAR cyclophosphamide INJECTABLE;INJECTION 087442-001 Feb 16, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Teva Parenteral NEOSAR cyclophosphamide INJECTABLE;INJECTION 040015-004 Apr 29, 1993 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Bedford NEOSAR cyclophosphamide INJECTABLE;INJECTION 087442-003 Feb 16, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Teva Parenteral NEOSAR cyclophosphamide INJECTABLE;INJECTION 040015-003 Apr 29, 1993 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Teva Parenteral NEOSAR cyclophosphamide INJECTABLE;INJECTION 040015-002 Apr 29, 1993 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Merck
Cipla
Johnson and Johnson
Baxter
Fuji
Novartis
Queensland Health
Daiichi Sankyo
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot